A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival rate at 2 months
2 months
No
PENEL Nicolas, MD
Principal Investigator
Centre Oscar Lambret
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
PAL-ANGI 0601
NCT00420563
September 2006
July 2009
Name | Location |
---|